Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.40 |
| ▸ | FABP7 | O15540 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | FDFT1 | P37268 | 2/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | FNTA | P49354 | 1/20 | 0.37 |
| ▸ | FNTB | P49356 | 1/20 | 0.37 |
| ▸ | MDM4 | O15151 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29399007 | 1.00 | FABP5 (0.40) | FABP5FABP7KMT2AFDFT1CASP3 | |
| SCHEMBL30116841 | 0.91 | ITGB3 (0.38) | FABP5FABP7KMT2AFDFT1 | |
| SCHEMBL26312569 | 0.90 | KMT2A (0.40) | FABP5FABP7KMT2AFDFT1CASP3 | |
| SCHEMBL30686148 | 0.90 | FABP5 (0.43) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL30792912 | 0.90 | FABP5 (0.43) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL24633869 | 0.90 | FABP5 (0.43) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL29277314 | 0.90 | FABP5 (0.43) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL21896097 | 0.87 | FABP5 (0.43) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL30670326 | 0.87 | FABP5 (0.43) | FABP5FABP7KMT2ACASP3EPHX2 | |
| SCHEMBL23056464 | 0.87 | FABP5 (0.43) | FABP5FABP7KMT2ACASP3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295221-A1 | EFFICIENT PEPTIDE CONDENSATION METHOD FOR DIFFICULT SEQUENCES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-09-21 | — | — | US | disclosed |
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-7659364-B2 | N-methyl-homocysteines and their use as well as process for their production | CIS BIO INTERNATIONAL (FR) | 2010-02-09 | — | — | US | disclosed |
| EP-1444194-B1 | N-METHYL-HOMOCYSTINES, USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF | CIS BIO INT (FR) | 2009-12-09 | — | — | EP | disclosed |
| EP-1444194-A1 | N-METHYL-HOMOCYSTINES, USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-08-11 | — | — | EP | disclosed |
| US-20030120032-A1 | N-methyl-homocysteines and their use as well as process for their production | SCHERING AG (DE) | 2003-06-26 | — | — | US | disclosed |
| WO-2003042163-A1 | N-METHYL-HOMOCYSTINES, USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030120032-A1 | N-methyl-homocysteines and their use as well as process for their production | BHMT, BHMT2, AHCY | FABP5 2008/4885FABP7 649/4885KMT2A 553/4885 |
| US-20230295221-A1 | EFFICIENT PEPTIDE CONDENSATION METHOD FOR DIFFICULT SEQUENCES | NGLY1, VIP, DNPEP | FABP5 2084/4885FABP7 1329/4885KMT2A 3727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.